Association of patient sex with chemotherapy-related toxic effects: A retrospective analysis of the PETACC-3 trial conducted by the EORTC gastrointestinal group

A partir des données de patients atteints d'un cancer colorectal de stade II ou III inclus dans un essai de phase III évaluant l'efficacité d'un traitement adjuvant à base de fluorouracile, de leucovorine ou d'une chimiothérapie de type FOLIFIRI, cette étude rétrospective analyse l'association entre le sexe du patient et la survenue d'événements indésirables induits par les chimiothérapies

Résumé en anglais

Sex is one of several known factors responsible for the wide interpatient variability in the dose-effect relationship of drugs. It affects both pharmacokinetics and pharmacodynamics. Data on the clinical impact of sex on chemotherapy-related toxic effects are lacking for colorectal cancer (CRC). The aim of this study is to evaluate the association of sex with incidence and severity of chemotherapy-related toxic effects in patients with stage II and III CRC treated with adjuvant fluorouracil and leucovorin or FOLFIRI (a combination therapy consisting of leucovorin, fluorouracil, and irinotecan hydrochloride) in the previously reported PETACC-3 trial.